Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03565328 Not yet recruiting - Heart Failure Clinical Trials

The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects

Start date: June 26, 2018
Phase: Phase 2
Study type: Interventional

Background: People are living longer and are more likely to survive a heart attack if they have one. Longer life expectancy is good but it also means more people get chronic heart failure over time. This is a condition in which the heart doesn't pump blood as well as it should. Treatment of chronic heart failure has not improved much in a few decades. Researchers want to see if giving a dietary supplement to people with heart failure can help their heart function. The supplement is nicotinamide riboside (NR). Objective: To study how NR affects skeletal muscle function in people with heart failure. Eligibility: Adults ages 18-70 with clinically stable systolic heart failure Design: Participants will be screened with a medical history and physical exam. They will answer demographic questions and review their current medical treatments. They will have blood and urine tests. They will have an echocardiogram. This uses sound waves to test heart function. Participants will have 8 study visits over 16 weeks. At these visits, they will have some of the following: Repeat of screening tests Skin sample taken Skeletal muscle exercise NMR spectroscopy. Muscles will be measured while participants do foot exercises. Cardiopulmonary exercise testing. Participants may ride a stationary bike or walk on a treadmill. A facemask will analyze their breath. Heart and blood pressure measurements will be taken. Participants will take the supplement in pill form each day for 12 weeks. Pill bottles will be checked at study visits. Participants should not significantly change their activity levels during the study.

NCT ID: NCT03564860 Not yet recruiting - Heart Failure Clinical Trials

HBP Device EGM Data Collection

Start date: June 2018
Phase:
Study type: Observational

This is a single-arm, non-randomized, non-blinded study designed to collect device data in patients with permanent His bundle (HB) pacing lead and an existing Abbott permanent pacemaker, defibrillator, or cardiac resynchronization device. Prospective data collection includes surface electrocardiograms, intracardiac electrograms, and pacing parameters, recorded during a patient visit. Additional retrospective data collection includes procedural data during the HB pacing lead and device implant. Up to 200 subjects will participate in this clinical investigation. The clinical investigation will be conducted at up to 8 centers worldwide. The total duration of the clinical investigation is expected to be 1 year, including enrollment and data collection from all subjects.

NCT ID: NCT03560323 Not yet recruiting - Heart Failure Clinical Trials

Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class II-III New York Heart Association (NYHA).

NCT ID: NCT03560206 Recruiting - Heart Failure Clinical Trials

Effects of Family Sodium Watcher Program on Outcomes in Heart Failure Patient-Family Caregiver Dyads

FAMSWAP
Start date: March 1, 2015
Phase: N/A
Study type: Interventional

The Family Sodium Watcher program in this study is designed to improve adherence to a sodium restricted diet in patients with HF using strategies that educate both patients and family caregivers about sodium monitoring and that stress a gradual progressive adaptation to low sodium food for both patients and family caregivers.

NCT ID: NCT03557255 Completed - Heart Failure Clinical Trials

Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

The objective of this pilot study is to evaluate the efficacy and safety of preoperative administration of levosimendan in patients with chronic heart failure scheduled for major abdominal cancer surgery assuming the reduction of both perioperative morbidity and mortality.

NCT ID: NCT03555318 Not yet recruiting - Heart Failure Clinical Trials

Intervention by a Cardiologist and Geriatrician in Elderly Patients After Admission Due to Heart Failure.

Start date: June 14, 2018
Phase: N/A
Study type: Interventional

Randomized clinical trial in which patients with a recent admission for heart failure in the cardiology department of the Hospital de Mar will be randomized to usual follow-up (cardiologist of the Heart Failure Unit) or follow-up by cardiologist and intervention by the geriatrician. This visit will be done at the same time. The main gial of this study is to evaluate whether the combined intervention of a cardiologist and a geriatrician reduces hospital all-cause rehospitalizations at 1 year.

NCT ID: NCT03555123 Not yet recruiting - Clinical trials for Acute Decompensated Heart Failure

Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

Start date: June 30, 2018
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, Multicenter, parallel, placebo-controlled study

NCT ID: NCT03554291 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

REHAB-PH
Start date: July 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.

NCT ID: NCT03554200 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

EMPA Acute Heart Failure

Start date: June 2018
Phase: Phase 2
Study type: Interventional

In this study the investigators are aiming to treat patients with acute heart failure with or without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin on heart failure hospitalization in the EMPA-REG OUTCOME trial, the investigators do expect a similar beneficial effect to be present in patients with acute heart failure. Acute heart failure is a state of hydropic decompensation resulting in dyspnea and congestions, caused by different etiologies of cardiac disease. Recompensation is reached by application of diuretic drugs and fluid restriction.

NCT ID: NCT03553303 Recruiting - Clinical trials for Heart Failure, Systolic

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Start date: July 2018
Phase: Phase 4
Study type: Interventional

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.